|
|
|
1
|
A bill to be entitled |
2
|
An act relating to public records and public meetings |
3
|
exemptions; amending s. 1004.445, F.S.; creating a public |
4
|
records exemption for proprietary confidential business |
5
|
information owned or controlled by the Florida Alzheimer's |
6
|
Center and Research Institute; categorizing specified |
7
|
types of information as proprietary confidential business |
8
|
information; defining "managed care"; providing for access |
9
|
to proprietary confidential business information by |
10
|
specified agencies; creating a public meetings exemption |
11
|
for specified meetings or portions of meetings of the |
12
|
governing board of the Florida Alzheimer’s Center and |
13
|
Research Institute; providing for future review and repeal |
14
|
of the exemption; providing a statement of public |
15
|
necessity; providing for construction of the act in pari |
16
|
materia with laws enacted during the Regular Session of |
17
|
the Legislature; providing an effective date. |
18
|
|
19
|
Be It Enacted by the Legislature of the State of Florida: |
20
|
|
21
|
Section 1. Subsection (9) of section 1004.445, Florida |
22
|
Statutes, is amended, and subsection (10) is added to said |
23
|
section, to read: |
24
|
1004.445 Florida Alzheimer's Center and Research |
25
|
Institute.-- |
26
|
(9)(a)The following information is confidential and |
27
|
exempt from the provisions of s. 119.07(1) and s. 24(a), Art. I |
28
|
of the State Constitution: |
29
|
1.(a)Personal identifying information relating to clients |
30
|
of programs created or funded through the Florida Alzheimer's |
31
|
Center and Research Institute which is held by the institute, |
32
|
the University of South Florida, or theState Board of Education |
33
|
or by persons who provide services to clients of programs |
34
|
created or funded through contracts with the Florida Alzheimer's |
35
|
Center and Research Institute; |
36
|
2.(b) Any medical or health records relating to patients |
37
|
heldwhich may be created or received by the institute; and |
38
|
3.(c)Proprietary confidential business information. As |
39
|
used in this subparagraph, the term "proprietary confidential |
40
|
business information” means information, regardless of its form |
41
|
or characteristics, which is owned or controlled by the |
42
|
institute; is intended to be and is treated by the institute as |
43
|
private and the disclosure of which would harm the business |
44
|
operations of the institute; has not been intentionally |
45
|
disclosed by the institute unless pursuant to law, an order of a |
46
|
court or administrative body, a legislative proceeding pursuant |
47
|
to s. 5, Art. III of the State Constitution, or a private |
48
|
agreement that provides that the information may be released to |
49
|
the public; and which is information concerning: |
50
|
a.Materials that relate to methods of manufacture or |
51
|
production, potential trade secrets, potentially patentable |
52
|
material, actual trade secrets as defined in s. 688.002, or |
53
|
proprietary information received, generated, ascertained, or |
54
|
discovered during the course of research conducted by or through |
55
|
the institute and business transactions resulting from such |
56
|
research; |
57
|
b.(d) The identity of a donor or prospective donor to the |
58
|
instituteFlorida Alzheimer's Center and Research Institutewho |
59
|
wishes to remain anonymous, and all information identifying such |
60
|
donor or prospective donor; |
61
|
c.(e)Any information received by the institute in the |
62
|
performance of its duties and responsibilities which is |
63
|
otherwise confidential and exempt by law; and |
64
|
d.(f)Any information received by the institute from a |
65
|
person from this oranother state or nation or the Federal |
66
|
Government which is otherwise exempt or confidential or exempt |
67
|
pursuant to this or anotherthatstate's or nation's laws or |
68
|
pursuant to federal law; |
69
|
e. Internal auditing controls and reports of internal |
70
|
auditors; |
71
|
f. Contracts for managed-care arrangements, including |
72
|
preferred provider organization contracts, health maintenance |
73
|
organization contracts, and exclusive provider organization |
74
|
contracts, and any documents directly relating to the |
75
|
negotiation, performance, and implementation of any such |
76
|
contracts for managed-care arrangements; |
77
|
g. Bids or other contractual data, banking records, and |
78
|
credit agreements the disclosure of which would impair the |
79
|
efforts of the institute to contract for goods or services on |
80
|
favorable terms; |
81
|
h. Information relating to private contractual data, the |
82
|
disclosure of which would impair the competitive interest of the |
83
|
provider of the information; |
84
|
i. Corporate officer and employee personnel information; |
85
|
j. Information relating to the proceedings and records of |
86
|
the credentialing panels and committees and of the governing |
87
|
board of the institute relating to credentialing; |
88
|
k. Minutes of meetings of the governing board of the |
89
|
institute, except minutes of meetings open to the public |
90
|
pursuant to subsection (10); and |
91
|
l. Information that reveals plans for marketing services |
92
|
that the institute reasonably expects to be provided by |
93
|
competitors. |
94
|
|
95
|
As used in this subparagraph, the term "managed care” means |
96
|
systems or techniques generally used by third-party payors or |
97
|
their agents to affect access to and control payment for health |
98
|
care services. Managed-care techniques most often include one or |
99
|
more of the following: prior, concurrent, and retrospective |
100
|
review of the medical necessity and appropriateness of services |
101
|
or site of services; contracts with selected health care |
102
|
providers; financial incentives or disincentives related to the |
103
|
use of specific providers, services, or service sites; |
104
|
controlled access to and coordination of services by a case |
105
|
manager; and payor efforts to identify treatment alternatives |
106
|
and modify benefit restrictions for high-cost patient care. |
107
|
(b) The Auditor General, the Office of Program Policy |
108
|
Analysis and Government Accountability, and the State Board of |
109
|
Education, pursuant to their oversight and auditing functions, |
110
|
must be given access to all proprietary confidential business |
111
|
information upon request and without subpoena and must maintain |
112
|
the confidentiality of information so received.
|
113
|
(c)Any governmental entity that demonstrates a need to |
114
|
access such confidential and exempt information in order to |
115
|
perform its duties and responsibilities shall have access to |
116
|
such information and shall otherwise keep such information |
117
|
confidential and exempt. This section is subject to the Open |
118
|
Government Sunset Review Act of 1995 in accordance with s. |
119
|
119.15 and shall stand repealed on October 2, 2006, unless |
120
|
reviewed and saved from repeal through reenactment by the |
121
|
Legislature. |
122
|
(10) Meetings or portions of meetings of the governing |
123
|
board of the Florida Alzheimer’s Center and Research Institute |
124
|
at which information is discussed that is made confidential and |
125
|
exempt pursuant to subsection (9) are exempt from s. 286.011 and |
126
|
s. 24(b), Art. I of the State Constitution. |
127
|
Section 2. Subsections (9) and (10) of s. 1004.445, |
128
|
Florida Statutes, are subject to the Open Government Sunset |
129
|
Review Act of 1995 in accordance with s. 119.15, Florida |
130
|
Statutes, and shall stand repealed on October 2, 2008, unless |
131
|
reviewed and saved from repeal through reenactment by the |
132
|
Legislature.
|
133
|
Section 3. The Legislature finds that it is a public |
134
|
necessity that proprietary confidential business information |
135
|
owned or controlled by the Florida Alzheimer's Center and |
136
|
Research Institute; internal auditing controls and reports of |
137
|
internal auditors; contracts for managed-care arrangements and |
138
|
any documents directly relating to the negotiation, performance, |
139
|
and implementation of any such contracts for managed-care |
140
|
arrangements; bids or other contractual data, banking records, |
141
|
and credit agreements; information relating to private |
142
|
contractual data; corporate officer and employee personnel |
143
|
information; information relating to the proceedings and records |
144
|
of the credentialing panels and committees and of the governing |
145
|
board of the Florida Alzheimer's Center and Research Institute |
146
|
relating to credentialing; minutes of meetings of the governing |
147
|
board of the institute; and information that reveals plans for |
148
|
marketing services that the institute reasonably expects to be |
149
|
provided by competitors be made confidential and exempt from |
150
|
public disclosure. The institute must compete directly with its |
151
|
private-sector counterparts. Its economic survival depends on |
152
|
the institute’s ability to so compete. As such, these exemptions |
153
|
are necessary because release of such information and records |
154
|
would adversely impact the institute in the competitive health |
155
|
care and medical research environment. Disclosure of such |
156
|
information and records would place the institute on an unequal |
157
|
footing in the marketplace as compared with private health care |
158
|
providers that are not required to disclose such confidential |
159
|
and exempt information and records. The highly confidential |
160
|
nature of Alzheimer-related research discoveries necessitates |
161
|
that the institute be authorized to maintain confidential |
162
|
information it receives from, or generates for, the sponsors of |
163
|
its research. Accordingly, disclosure of such information and |
164
|
records would impede the effective and efficient administration |
165
|
of the Florida Alzheimer’s Center and Research Institute and |
166
|
would create an unfair competitive advantage for persons or |
167
|
entities receiving such information. Also, such information and |
168
|
records contain information of a sensitive, personal nature |
169
|
regarding corporate officers and employees. Disclosure of such |
170
|
information could be harmful to the officer or employee. It is |
171
|
likewise a public necessity that the meetings of the governing |
172
|
board of the institute be closed in order to protect the |
173
|
competitive interest of the institute and to guarantee the |
174
|
ability of the governing board to fulfill its Alzheimer’s |
175
|
disease research and teaching mission for the benefit of the |
176
|
public. Closing access to such board meetings enables the boards |
177
|
to be more open and frank in the information so provided and |
178
|
discussed without the attendant fear that honest and truthful |
179
|
exchange of information will result in the public dissemination |
180
|
of information discussed that could be used to harm the |
181
|
institute and its members. Furthermore, disclosing information |
182
|
and records made confidential and exempt pursuant to the |
183
|
institute’s public records exemption via an open meeting defeats |
184
|
the purpose of the public records exemption. |
185
|
Section 4. If any law amended by this act was also amended |
186
|
by a law enacted at the 2003 Regular Session of the Legislature, |
187
|
such laws shall be construed as if they had been enacted at the |
188
|
same session of the Legislature, and full effect shall be given |
189
|
to each if possible. |
190
|
Section 5. This act shall take effect upon becoming a law. |